The Rs 479.21-crore IPO received bids for 55.25 crore shares against the total issue size of 75,21,297 shares, as per data available till 1900 hrs.
The category reserved for qualified institutional buyers (QIBs) was oversubscribed 73.18 times, while non-institutional investors received 225.30 times subscription.
Retail investors portion was also oversubscribed 8.55 times.
The firm, which runs a diagnostics laboratory chain, has come out with a public issue of up to 10,744,708 shares of Rs 10 each.
Thyrocare has raised Rs 144 crore through issuance of shares to 15 anchor investors.
The shares are proposed to be listed on NSE and BSE.
The issue is being managed by JM Financial Institutional Securities, Edelweiss Financial Services and ICICI Securities.
Thyrocare competes with diagnostics chains such as Dr Lal PathLabs, SRL Diagnostics, Metropolis Healthcare and Apollo Clinic.
Many healthcare firms like Alkem Laboratories, Dr Lal PathLabs and Narayana Hrudayalaya came out with their IPOs last year, while HealthCare Global Enterprises got listed on the stock exchanges last month.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
